Skip to content

Author

Fang Hao

We have 2 of 33 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Clinical and Molecular Outcomes of Dabrafenib/Trametinib-Based Combination Therapy in Acquired BRAF V600E-Mutant NSCLC Following Tyrosine Kinase Inhibitor Resistance: A Preliminary Single-Center Retrospective Study

Acquired BRAF V600E is an uncommon resistance mechanism after tyrosine kinase inhibitor (TKI) therapy in oncogene-driven non-small cell lung cancer (NSCLC), and the clinical value of dabrafenib/trametinib-based combination therapy remains unclear. This preliminary single-center retrospective study aimed to describe...

Dan Xu, Fang Hao, Xia Liu et al. · 0 citations
Open access Aug 2026

DNA Damage Response Alterations Stratify Response to ICI-Based Therapy in Advanced NSCLC with High PD-L1 Expression

Patients with multiple DNA damage response gene alterations showed distinct immune profiles, higher rates of durable clinical benefit, and longer progression-free survival, and these findings suggest that genomic DNA damage response alterations may help identify patients who are more likely to benefit from personalized...

Fang Hao, Lin-Lin Zhang, Dian-Sheng Zhong · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.